1 week Ago By ABMN Staff
Raymond James Financial Inc. acquired a new position in shares of Geron Co. ( NASDAQ:GERN – Free Report ) during the 4th quarter, Holdings Channel reports.
The fund acquired 69,705 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. A number of other hedge funds have also bought and sold shares of GERN. State Street Corp increased its stake in Geron by 28.
4% in the third quarter. State Street Corp now owns 28,961,671 shares of the biopharmaceutical company’s stock worth $131,486,000 after purchasing an additional 6,413,204 shares during the period. World Investment Advisors LLC raised its holdings in shares of Geron by 10,151.
4% in the third quarter. World Investment Advisors LLC now owns 1,029,553 shares of the biopharmaceutical company’s stock worth $4,674,000 after buying an additional 1,019,510 shares during the last quarter. Exome Asset Management LLC purchased a new position in shares of Geron in the third quarter worth about $4,109,000.
Barclays PLC increased its stake in shares of Geron by 114.9% in the third quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company’s stock worth $5,902,000 after acquiring an additional 694,931 shares during the period.
Finally, Wellington Management Group LLP boosted its stake in shares of Geron by 4.7% in the third quarter. Wellington Management Group LLP now owns 12,662,404 shares of the biopharmaceutical company’s stock worth $57,487,000 after buying an additional 570,580 shares during the last quarter.
Institutional investors own 73.71% of the company’s stock. Geron Trading Down 6.
5 % Shares of Geron stock opened at $1.30 on Friday. The company has a debt-to-equity ratio of 0.
04, a quick ratio of 2.74 and a current ratio of 2.89.
Geron Co. has a 1 year low of $1.19 and a 1 year high of $5.
34. The company’s fifty day moving average is $1.96 and its two-hundred day moving average is $3.
15. The company has a market capitalization of $827.98 million, a P/E ratio of -4.
06 and a beta of 0.66. Wall Street Analysts Forecast Growth GERN has been the subject of a number of analyst reports.
HC Wainwright reaffirmed a “neutral” rating on shares of Geron in a report on Wednesday, March 12th. Scotiabank decreased their target price on shares of Geron from $6.00 to $4.
00 and set a “sector outperform” rating on the stock in a report on Thursday, February 27th. Stifel Nicolaus decreased their price objective on shares of Geron from $8.00 to $4.
00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Needham & Company LLC reissued a “buy” rating and issued a $5.00 price objective on shares of Geron in a research note on Wednesday, March 12th.
Finally, Barclays reissued an “overweight” rating and set a $4.00 price objective (down from $9.00) on shares of Geron in a research report on Thursday, February 27th.
One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Geron presently has an average rating of “Moderate Buy” and a consensus target price of $5.
75. Get Our Latest Research Report on Geron About Geron ( Free Report ) Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
See Also Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Co. ( NASDAQ:GERN – Free Report ).
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter ..
